Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy‐free, first‐line treatment for PD‐L1‐positive non‐small cell lung cancer

Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy‐free, first‐line treatment for PD‐L1‐positive non‐small cell lung cancer

Abstract Background Nivolumab plus ipilimumab (N‐I) or pembrolizumab (PEM) is associated with survival improvement as chemotherapy‐free, first‐line treatment for patients with advanced non‐small cell lung carcinoma (NSCLC) and positive programmed cell death ligand 1 (PD‐L1). However, no direct compa...

Full description

Bibliographic Details
Main Authors: Yixin Zhou, Yaqiong Zhang, Guifang Guo, Xiuyu Cai, Hui Yu, Yanyu Cai, Bei Zhang, Shaodong Hong, Li Zhang
Format: Article
Language:English
Published: Wiley 2020-03-01
Series:Clinical and Translational Medicine
Subjects:
ipilimumab
nivolumab
non‐small cell lung cancer
pembrolizumab
programmed cell death‐ligand 1
Online Access:https://doi.org/10.1002/ctm2.14

Internet

https://doi.org/10.1002/ctm2.14

Similar Items